

# Kishan S Parikh

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2392839/publications.pdf>

Version: 2024-02-01

28  
papers

546  
citations

686830

13  
h-index

642321

23  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1002  
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Identification of Patients at Risk for Incident Heart Failure With Preserved Ejection Fraction: Novel Approach to Echocardiographic Trends. <i>Journal of Cardiac Failure</i> , 2021, 27, 942-948.	0.7	0
2	Relationship of Nonalcoholic Fatty Liver Disease and Heart Failure With Preserved Ejection Fraction. <i>JACC Basic To Translational Science</i> , 2021, 6, 918-932.	1.9	41
3	Pulmonary Hypertension Subtypes and Mortality in CKD. <i>American Journal of Kidney Diseases</i> , 2020, 75, 713-724.	2.1	32
4	Treatment-related biomarkers in pulmonary hypertension patients on oral therapies. <i>Respiratory Research</i> , 2020, 21, 304.	1.4	3
5	Experience in Transitioning From Parenteral Prostaglandins to Selexipag in Pulmonary Arterial Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2020, 75, 299-304.	0.8	8
6	Applications of the Multisensor HeartLogic Heart Failure Monitoring Algorithm During the COVID-19 Global Pandemic. <i>JACC: Case Reports</i> , 2020, 2, 2265-2269.	0.3	9
7	Monitoring Pulmonary Arterial Hypertension Using an Implantable Hemodynamic Sensor. <i>Chest</i> , 2019, 156, 1176-1186.	0.4	32
8	Echocardiographic Assessment of Right Ventricular Function and Response to Therapy in Pulmonary Arterial Hypertension. <i>American Journal of Cardiology</i> , 2019, 124, 1298-1304.	0.7	13
9	Diverse cardiopulmonary diseases are associated with distinct xenon magnetic resonance imaging signatures. <i>European Respiratory Journal</i> , 2019, 54, 1900831.	3.1	47
10	Characteristics of Acute Heart Failure Hospitalizations Based on Presenting Severity. <i>Circulation: Heart Failure</i> , 2019, 12, e005171.	1.6	15
11	Outcomes of lung disease-associated pulmonary hypertension and impact of elevated pulmonary vascular resistance. <i>Respiratory Medicine</i> , 2019, 150, 126-130.	1.3	12
12	Clinical Features and Outcomes of Patients with Sarcoidosis-associated Pulmonary Hypertension. <i>Scientific Reports</i> , 2019, 9, 4061.	1.6	36
13	Impact of Age on Comorbidities and Outcomes in Heart Failure With Reduced Ejection Fraction. <i>JACC: Heart Failure</i> , 2019, 7, 1056-1065.	1.9	21
14	Cardiac Rehabilitation After Ventricular Assist Device Implantation. <i>JACC: Heart Failure</i> , 2018, 6, 140-142.	1.9	0
15	Systematic review and meta-analysis of endovascular and surgical revascularization for patients with chronic lower extremity venous insufficiency and varicose veins. <i>American Heart Journal</i> , 2018, 196, 131-143.	1.2	17
16	Dose Response of $\beta$ -Blockers in Adrenergic Receptor Polymorphism Genotypes. <i>Circulation Genomic and Precision Medicine</i> , 2018, 11, e002210.	1.6	8
17	Heart Failure With Preserved Ejection Fraction Expert Panel Report. <i>JACC: Heart Failure</i> , 2018, 6, 619-632.	1.9	103
18	Relation of Volume Overload to Clinical Outcomes in Acute Heart Failure (From ASCEND-HF). <i>American Journal of Cardiology</i> , 2018, 122, 1506-1512.	0.7	16

#	ARTICLE	IF	CITATIONS
19	Scope of Sacubitril/Valsartan Eligibility After Heart Failure Hospitalization. <i>Circulation</i> , 2017, 135, 2077-2080.	1.6	28
20	Exercise Training in Patients With Chronic Heart Failure and Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1683-1691.	1.2	45
21	Pharmacogenomics of Bucindolol in Atrial Fibrillation and Heart Failure. <i>Current Heart Failure Reports</i> , 2017, 14, 529-535.	1.3	2
22	Representativeness of Medicare Participants in the Jackson Heart Study for African American Medicare Beneficiaries. <i>Epidemiology</i> , 2017, 28, 740-746.	1.2	1
23	Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension. <i>Journal of Cardiovascular Pharmacology</i> , 2016, 67, 322-325.	0.8	12
24	Mode of Death After Acute Heart Failure Hospitalization—A Clue to Possible Mechanisms. <i>Circulation Journal</i> , 2016, 80, 17-23.	0.7	13
25	Relation of Angina Pectoris to Outcomes, Quality of Life, and Response to Exercise Training in Patients With Chronic Heart Failure (from HF-ACTION). <i>American Journal of Cardiology</i> , 2016, 118, 1211-1216.	0.7	11
26	Use of outcome measures in pulmonary hypertension clinical trials. <i>American Heart Journal</i> , 2015, 170, 419-429.e3.	1.2	17
27	PH Grand Rounds: Confronting the Challenge of Sarcoidosis-Associated Pulmonary Hypertension. <i>Advances in Pulmonary Hypertension</i> , 2015, 14, 166-169.	0.1	0
28	Potential Applications of Pharmacogenomics to Heart Failure Therapies. <i>Heart Failure Clinics</i> , 2014, 10, 599-606.	1.0	4